Acute and Chronic Disease Reports
Open Access

Alcoholic Hepatitis vs. Alcoholic Fatty Liver Disease: Its Diagnosis, Treatment and Prognosis

Mark Twain^{* *}Correspondence: Mark Twain, Department of Medicine, LMU University Hospital, Munich, Germany, Email:

Author info »

Description

A clinical syndrome known as alcoholic hepatitis (Alcoholic fatty liver disease) is characterised by acute-onset jaundice and abnormal liver enzyme levels when there has been prolonged heavy alcohol consumption. Significant morbidity and mortality are caused by high frequencies of concurrent infections, systemic inflammation, and multiorgan failure. According to a consensus definition provided by the National Institute on alcohol abuse and Alcoholism, the diagnosis of alcoholic hepatitis is predominantly clinical. Chest radiography and cultures of peritoneal fluid, blood, and urine should be part of the initial workup. Throughout the hospital stay, close observation for inflammation and organ failure is essential. Determine the severity of the disease and available treatments using laboratorybased prognostic scores, such as the Maddrey discriminant function and the model for end-stage Liver Disease.

The majority of supportive care, such as nutrition support and alcohol cessation, makes up the treatment for moderate disease. In the case of severe alcoholic hepatitis, corticosteroids are advised. On day 7 of treatment, the Lille score should be used to assess the patient's responsiveness to corticosteroid medication. Hospital doctors should work with a multidisciplinary team that includes, as necessary, dietitians, intensivists, gastroenterologists or hepatologists, substance abuse specialists, and nephrologists. Long-term follow-up should concentrate on alcohol abstinence, treating underlying cirrhosis, and, if necessary, assessing patients for liver transplantation. Patients with alcohol use disorders may benefit from pharmacologic treatment, which can help them keep their alcohol abstinence. Long-term prognosis is adversely affected by underlying cirrhosis and ongoing alcohol consumption.

Hepatic steatosis and cirrhosis are two pathologies that fall under the umbrella of alcohol-associated liver disease. Ascites, variceal haemorrhage, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, or hepatocellular carcinoma are all signs of decompensated liver disease. A clinical syndrome called alcoholic hepatitis is linked to acute jaundice and liver failure. Significant morbidity and mortality are caused by high frequencies of concurrent infections, systemic inflammation, and multiorgan failure.

Due to inconsistent disease diagnosis and overlap with concurrent, more readily diagnosed liver diseases like hepatitis C, estimating the incidence of alcoholic hepatitis is challenging. However, hospital admissions in the United States for alcoholic hepatitis are increasing, making up 0.83% of all admissions in 2010. Long-term and heavy alcohol consumption, youth, genetic vulnerability, greater body mass index, and coexisting liver illness are risk factors for the condition. With a 28-day mortality rate of 16% to 30% and a one-year mortality rate of 56%, severe alcoholic hepatitis has a significant overall and inhospital mortality rate. Long-term prognosis is adversely affected by underlying cirrhosis and ongoing alcohol consumption.

The National Institute on Alcohol Abuse and Alcoholism created a consensus statement for identifying the condition due to past diversity in alcoholic hepatitis diagnosis. In addition to acute-onset jaundice, specific laboratory abnormalities, and a recognisable history of alcohol use, the diagnosis is primarily clinical (i.e., long-term consumption of roughly three standard drinks daily for women and four standard drinks daily for men). Only when the diagnosis is ambiguous and a precise diagnosis may affect care is a liver biopsy required.

Conclusion

Acute-onset jaundice and abnormal liver enzyme levels are characteristics of alcoholic hepatitis. High frequencies of concurrent infections, systemic inflammation, and multiorgan failure significantly increase morbidity and mortality. The majority of supportive care, including assistance with nutrition and abstinence from alcohol, is used in the treatment of moderate disease. Acute jaundice and liver failure are two clinical syndromes related to alcoholic hepatitis. Risk factors for the disorder include alcohol use, young age, feminine sex, genetic susceptibility, higher body mass index, and concomitant liver disease. 28-day mortality rates for alcohol hepatitis range from 16% to 30%, and one-year mortality rates are 56%.